Marvin Chang Jui Lim

Dr. Marvin Chang Jui Lim

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2018 in Diagnostics
Verified
Journal Article
Open access
PDF file
MLMarvin Chang Jui Lim
Marvin Chang Jui Lim
ABAnne-Marie Baird
Anne-Marie Baird
JAJohn Aird
John Aird
JGJohn Greene
John Greene
DKDhruv Kapoor
Dhruv Kapoor
SFStephen Patrick Finn
Stephen Patrick Finn
The treatment landscape of prostate cancer has evolved rapidly over the past five years. The explosion in treatment advances has been witnessed in parallel with significant progress in the field of molecular biomarkers. The advent of next-generation sequencing has enabled the molecular profiling of the genomic and transcriptomic architecture of prostate and other cancers. Coupled with this, is a renewed interest in the role of non-coding RNA (ncRNA) in prostate cancer biology. ncRNA consists of several different classes including small non-coding RNA (sncRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA). These families are under active investigation, given their essential roles in cancer initiation, development and progression. This review focuses on the evidence for the role of RNAs in prostate cancer, and their use as diagnostic and prognostic markers, and targets for treatment in this disease.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LPLisa Mary Prior
Lisa Mary Prior
EHEmily Harrold
Emily Harrold
COConnor Gerard O'Leary
Connor Gerard O'Leary
KNKillian Nugent
Killian Nugent
JGJack Patrick Gleeson
Jack Patrick Gleeson
CKCatherine Kelly
Catherine Kelly
E14534 Background: Checkpoint inhibitors have been shown to improve survival outcomes in patients with metastatic malignant melanoma. However, the use of these agents is associated with a unique spectrum of immune related toxicities. Despite this, durable responses on immunotherapy are still possible even in patients who experience grade 3 toxicities. Furthermore, trials to date have shown that steroids do not appear to affect survival. We present the long term data on real world toxicities and response rates for patients treated previously with Ipilimumab at a national academic cancer centre. Methods: All patients treated previously with Ipilimumab at our centre were identified from pharmacy records. We performed a retrospective paper and electronic review and extracted relevant demographic data (age, sex) and clinical data (number of cycles, incidence and grade of immune related adverse events, interruption/cessation of therapy, need for immunosuppression, initial response to treatment and time to progression). Results: 33 patients with metastatic malignant melanoma were treated with Ipilimumab at our centre from 2011 to 2016. The incidence of G1, G2 and G3 toxicities was 33% (n = 11), 6% (n = 2) and 29% (n = 9), respectively. 23% (n = 7) of patients required steroids and 6% (n = 2) required TNF-a inhibitors. Treatment was stopped in 23% of patients due to Grade 3 toxicites. Of the grade 3 toxicities, colitis was the most common (46%, n = 6). In addition, rare toxicities were idenfied including orbital myositis (1 patient) and myelitis (1 patient). The response rate in the patient subset that required steroids was 42% vs. 15% in those that did not. The median duration of response in those that required and did not require steroids was 8 and 7 months respectively. Conclusions: Higher response rates and a longer median duration of response was seen in patients with grade 3 toxicities requiring steroids. The incidence of toxicities may reflect increased immunotherapy activity, thus leading to superior response rates. Further studies are needed to assess if earlier use of steroids to mitigate toxicities and the possibility of "treating through toxicities" could lead to increased efficacy of these agents in the future.

20 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MLMarvin Chang Jui Lim
Marvin Chang Jui Lim
ABAnne-Marie Baird
Anne-Marie Baird
JGJohn Greene
John Greene
CMCiara McNevin
Ciara McNevin
KRKarine E Ronan
Karine E Ronan
SFStephen Patrick Finn
Stephen Patrick Finn
Background: Enzalutamide is part of the treatment regimen for metastatic castration-resistant prostate cancer (MCRPC). However, both intrinsic and acquired resistance to the drug remain substantial clinical quandaries. circRNAs, a novel type of non-coding RNA, have been identified in a number of cancers including prostate cancer and have been associated with cancer development and progression. circRNAs have shown great potential as clinically useful blood-based ‘liquid biopsies’ and as therapeutic targets in prostate cancer. The aim of this study was to examine the role of circRNA transcripts in enzalutamide-resistant prostate cancer cells and assess their utility as biomarkers. Methods: An isogenic cell line model of enzalutamide resistance was subjected to circRNA microarray profiling. Several differentially expressed circRNAs, along with their putative parental genes were validated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). circRNAs of interest were stably overexpressed in the control cell line and drug sensitivity was assessed using an ELISA-based proliferation assay. The candidate circRNA, hsa_circ_0001275, was measured in patient plasma samples using RT-droplet digital PCR (RT-ddPCR). Results: hsa_circ_0001275 and its parental gene, PLCL2, were significantly up-regulated in strongly resistant clones vs. control (p < 0.05). Overexpression of hsa_circ_0001275 in the control cell line resulted in increased resistance to enzalutamide (p < 0.05). While RT-ddPCR analysis of hsa_circ_0001275 expression in plasma samples of 44 clinical trial participants showed a trend that mirrored the stages of disease activity (as defined by PSA level), the association did not reach statistical significance. Conclusions: Our data suggest that increased levels of hsa_circ_0001275 contribute to enzalutamide resistance. hsa_circ_0001275 plasma expression showed a trend that mirrors the PSA level at specific disease time points, indicating that circRNAs mirror disease recurrence and burden and may be associated with enzalutamide resistance.